Nov 12, 2012 10:31AM Notable Analyst Rating Changes 11/12: (SQNM) (DIS) (KLAC) Upgraded; (GRMN) (JCP) (SD) Downgraded
Nov 12, 2012 09:35AM StreetInsider.com Pre-Open Movers 11/12: (TIE) (JEF) (GILD) Higher; (CLVS) (STSI) (GRMN) Lower (more...)
Nov 12, 2012 08:46AM Needham & Company Starts Dendreon (DNDN) at Buy
Sep 6, 2012 09:29AM Pre-Open Movers 9/6: (OREX) (MW) (CALL) Higher; (OCZ) (PAY) (WCRX) Lower (more...)
May 23, 2012 10:50AM Notable Analyst Rating Changes 05/23: (SBUX) (AMAT) (WMB) Upgraded; (NDAQ) (PSO) (ARBA) Downgraded
May 8, 2012 11:02AM Notable Analyst Rating Changes 05/08: (VRTX) (XCO) (EA) Upgraded; (EP) (BP) (AMX) Downgraded
Feb 1, 2012 10:53AM Morning Movers 02/01: (COCO) (MGAM) (KTCC) (RSYS) Higher; (IXYS) (JDAS) (KWK) Lower
Dec 23, 2011 07:35AM Needham & Company 2012 Biotech Preview
Nov 11, 2011 11:26AM Notable Analyst Rating Changes 11/11: (LSCC) (GNW) (DNDN) Upgraded; (CAG) (BRLI) (FSLR) Downgraded
Sep 16, 2011 11:01AM Notable Analyst Rating Changes 09/16: (EBAY) (LYG) (REV) Upgraded; (RIMM) (ADBE) (SSYS) Downgraded
Aug 4, 2011 02:34PM Unusual 11 Mid-Day Movers 08/04: (WWWW) (ATSG) (EM) Higher; (DNDN) (AIB) (NCIT) Lower
Aug 4, 2011 02:02PM Notable 52-Week Highs and Lows of the Day 08/04: (KFT) (AUY) (CBOU) High; (DNDN) (PMI) (ENTR) Low
Aug 4, 2011 11:22AM Morning Movers 08/04: (WWWW) (SRDX) (ATSG) (LHCG) Higher; (DNDN) (ENTR) (NCIT) (GTIV) (CLWR) Lower
Aug 4, 2011 10:58AM Notable Analyst Rating Changes 08/04: (EMC) (MCD) (TIF) Upgraded; (DNDN) (WFR) (WLT) Downgraded
Aug 4, 2011 10:21AM UPDATE - Needham & Company downgrades Dendreon (DNDN) from Buy to Hold; Strong Science, Modest Adoption but Lowering our PROVENGE Sales Ests Given N-T Hurdles
Aug 4, 2011 08:16AM Needham & Company Downgrades Dendreon (DNDN) to Hold
Jul 1, 2011 07:41AM Needham & Company Reiterates a 'Buy' on Dendreon (DNDN); Three Events Help Facilitate the One Goal of Increasing PROVENGE Sales
Jun 8, 2011 08:03AM Needham & Company Maintains a 'Buy' on Dendreon (DNDN); ASCO Mtg Presentations Highlight PROVENGE Clinical Benefits Beyond Overall Survival
May 19, 2011 08:24AM Needham & Co Highlights Seattle Genetics (SGEN), Pharmacyclics (PCYC), and Dendreon (DNDN) Ahead of ASCO
May 3, 2011 07:49AM Needham & Company Reiterates a 'Buy' on Dendreon (DNDN); Company Management Executing on Sales/Manufacturing Plans to Expand PROVENGE Use
Apr 12, 2011 07:39AM Needham & Company on Biotechnology & Life Sciences: Oncology / Hematology Review from the 2011 Needham Healthcare Conference
Mar 31, 2011 07:44AM Needham & Company Maintains a 'Buy' on Dendreon (DNDN); Did You Get the Memo? CMS Supports the Coverage of PROVENGE for On-Label Use
Mar 2, 2011 07:54AM Needham & Company Reiterates a 'Buy' on Dendreon (DNDN); PROVENGE Marches On, with Manufacturing Plans on Schedule
Jan 7, 2011 03:07PM Needham & Company reiterates a 'Buy' on Dendreon (DNDN); Why Wait? Early New Year Plans to Expand PROVENGE Marketing in the US Alongside Expanded Manufacturing Capacity
Jan 5, 2011 08:05AM Needham & Company Reiterates a 'Buy' on Dendreon (DNDN); PROVENGE Demand > Supply, Manufacturing on Track, Reimbursement Concerns Eased
Nov 18, 2010 03:54PM Analysts Remain Bullish on Dendreon (DNDN) Following Positive MEDCAC Review
Nov 18, 2010 07:52AM Needham & Company Reiterates a 'Buy' on Dendreon (DNDN); Clear Messages Emerged That On-Label PROVENGE Use Consistent with Survival Benefit
Aug 4, 2010 08:11AM Needham & Company Reiterates a 'Buy' on Dendreon (DNDN); Potential Product Revenue and Manufacturing Build-Out
Jul 12, 2010 07:54AM Needham & Company Reiterates a 'Buy' Rating Dendreon (DNDN); 2Q10 Earnings Preview
Apr 30, 2010 02:03PM Needham & Company Maintanis a 'Buy' on Dendreon (DNDN); Raises PT to $62
Apr 30, 2010 01:47PM Wall Street Giddy About Dendreon (DNDN) After Provenge Approval; Where Are Shares Headed?
Apr 30, 2010 08:47AM Needham & Company Raises Price Target On Dendreon (DNDN) to $62
Apr 14, 2010 11:03AM Notable Analyst Rating Changes 04/14: AIB, ERIC, MCD, CREE Upgraded; POT/MOS, TWC/DTV, DNDN, NOK Downgraded
Mar 4, 2010 08:48AM Needham & Company Says Updated PROVENGE Data from Dendreon (DNDN) "Further Outline the Robustness"
Jan 7, 2010 10:54AM Notable Analyst Rating Changes 1/7: BAC, SHLD, THC, IT, ZUMZ, CITP Upgraded; RAI, AA, RAD, WEN, BEXP Downgraded
Dec 11, 2009 06:47AM Dendreon (DNDN) Prices 15M Common Offering at $24.75/Share
Jul 23, 2009 10:01AM Needham Comments on "Who's Next" In Biotech After Bristol-Myers (BMY) Buys Medarex (MEDX)
May 18, 2009 10:16AM Needham Discusses Next Steps For Dendreon's (DNDN) PROVENGE
May 11, 2009 11:19AM Dendreon (DNDN) Sees Continued Upside On 'Table-Pounding' Analyst Comments
Apr 29, 2009 10:59AM Needham Upgrades Dendreon (DNDN) To Buy, With 'Street High' $38 Price Target
Apr 14, 2009 12:56PM Needham & Co Positive About Dendreon (DNDN) PROVENGE Results, Maintains Hold On Valuation